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Malignancy validation in a United States registry
of rheumatoid arthritis patients
Mark C Fisher1*, Victoria Furer2, Marc C Hochberg3, Jeffrey D Greenberg4, Joel M Kremer5, Jeff R Curtis6,
George Reed7, Leslie Harrold8 and Daniel H Solomon9
Abstract
Background: Physician reporting is commonly used to ascertain adverse events or outcomes measured in
epidemiologic studies. However, little is known on the accuracy of physician reported malignancies compared to
pertinent medical record review in large cohort studies.
Methods: The Consortium of Rheumatology Researchers of North America (CORRONA) registry gathers physician-
completed questionnaires for rheumatoid arthritis (RA) patients, including request for information on incident
malignancies, approximately every three months. For incident malignancies reported from October 1st, 2001,
through December 31st, 2007, we retrospectively requested completion of a Targeted Adverse Event (TAE) form for
additional information as well as primary source documents to adjudicate the malignancy reports. CORRONA has
employed a prospective request for source documentation for these events since 2008. We classified each
malignancy as definite, probable, possible, or not a malignancy.
Results: From 20,837 RA patients enrolled in CORRONA, 461 incident malignancies were initially reported on
physician questionnaires. After review of returned source documents with adjudication, 234 were deemed definite,
69 probable, 101 possible, and 57 not an incident malignancy. The positive predictive value (PPV) of initial physician
report of a malignancy versus “definite or probable” malignancy based on adjudication was 0.66 (95% CI 0.61 - 0.70).
The PPV was 0.68 (95% CI 0.63 – 0.72) when the subsequent TAE form also confirmed the presence of malignancy.
When possible malignancies were included, the PPV of physician-reported malignancies without a subsequent TAE
form increased to 0.86 (0.83 – 0.89), and with a subsequent TAE form, 0.89 (0.85-0.91).
Conclusion: Twelve percent of initial physician reports of incident malignancy could not be confirmed with review
of source documents. The most common reason for lack of confirmation was inability to obtain documents or
insufficient data in source materials. These results suggest that timely collection of relevant medical records and an
adjudication process are required to improve the accuracy of cancer reporting in epidemiologic studies.
Keywords: Malignancy, Rheumatoid arthritis, Registry, Validation
Background
Rheumatoid Arthritis (RA) is an auto-immune, multi-
system inflammatory disease with significant morbidity
and mortality. In addition to its articular manifestations,
RA has a variety of extra-articular complications, includ-
ing malignancy [1,2]. The impact of immunosuppressive
treatments used to manage patients with RA may also
influence the development of malignancies, as each of
these treatments cause perturbations of the immune
system that may lead to malignancy [3-6]. Because of the
influences of disease activity and therapy on the immune
system of patients with RA, as well as the relative infre-
quent occurrence of many types of malignancy, it can be
difficult to assess the impact of a specific medication on
the risk of malignancy.
To date, several epidemiologic and pharmacoepide-
miology studies have been performed to assess the rate
of malignancy in RA patients treated with Tumor
Necrosis Factor a inhibitors (TNFi) [7-18]. Sources for
these datasets include national registries, prospective
cohorts, and administrative databases. Cancer outcomes
* Correspondence: mfisher6@partners.org
1Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114, USA
Full list of author information is available at the end of the article
© 2012 Fisher et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Fisher et al. BMC Musculoskeletal Disorders 2012, 13:85
http://www.biomedcentral.com/1471-2474/13/85
in these studies have been identified based on national
cancer registers, patient self-report, physician report, ad-
ministrative claims, and medical records. In the United
States, common methods for ascertainment of malig-
nancy among RA patients include patient self-report or
physician report. Another approach is mining of centra-
lized administrative databases, often using claims data or
ICD-9 codes to document presence of malignancy, as in
the US, national malignancy registries do not exist. The
Surveillance Epidemiology and End Results (SEER) regis-
try does capture data on incident malignancies in the
US, but it only collects data for a handful of states as
well as some additional, separate urban areas. There are
also state specific cancer registries, however, between the
overall number of RA patients and the overall low rate
of malignancy among RA patients, they often do not
have the power necessary for pharmacoepidemiologic
studies. In addition, individual patient information is not
available in many of these registries to permit linkage to
observational registries of other diseases. Outside the
United States, in addition to the above methods, many
countries have national cancer registries where reporting
of all incident malignancies to a central database with
confirmation is mandatory.
To classify incident cancers in a large cohort of
patients with RA where a cancer registry was not avail-
able, primary records were requested to validate the ma-
lignancy. We developed an adjudication process and
tested the accuracy of physician-reported incident can-
cers, using pertinent medical records as the gold
standard.
Methods
Study population
The Consortium of Rheumatology Researchers of
North America (CORRONA) is an independent regis-
try of RA patients that has collected clinical, labora-
tory, imaging, medication, and toxicity data since
2001[19]. To date, it has collected data from over 100
rheumatology practices and over 300 participating
rheumatologists throughout the United States, both
academic and private, with over 20,000 RA patients
enrolled. Data are collected from both patients and
their treating rheumatologists using questionnaires,
which gather information on disease duration, prog-
nostic information, physician and patient-determined
standardized disease severity and activity measures,
medical comorbidities, use of medications including
DMARDs, laboratory values, and adverse events [20].
Follow-up assessments are requested at four month
intervals and completed during routine clinical
encounters. Approvals for participation in the COR-
RONA registry are obtained from the respective Insti-
tutional Review Boards of participating academic sites
and a central Institutional Review Board for private
practice sites.
At each visit, physicians complete questionnaires that
include information about new comorbidities, including
cancer. For the period of this study (10/01 to 12/07),
follow-up Targeted Adverse (TAE) Forms and request for
source documents were performed retrospectively. Since
2008, TAE forms and requests for source documents are
initiated at the time of the initial physician report. Only the
reporting rheumatologists’ office can request medical
records due to privacy requirements established by the
CORRONA registry. The medical records requested in-
clude pathology reports, hospital discharge summaries,
notes from an oncologist, and/or notes from a primary care
physician.
Source documents
After the adverse event forms were returned, all sites were
asked to provide source documents to corroborate the
diagnosis of an incident malignancy. If source documents
were not received within a specified period of follow-up, a
second request was made. If source documents were still
not submitted, a second questionnaire asking for validation
specifically of the organ of the malignancy, pathology re-
port, and date of onset was requested.
Medical record review
All malignancies reported between 10/1/2001 and 12/31/
2007 were evaluated for this analysis. Once all data, in-
cluding the adverse event forms and primary source docu-
ments, were received, they were reviewed using a
structured abstraction form. In the analyses reported here,
all data were reviewed and abstracted separately by two
investigators (MF and VF). The abstracted data were then
compared, and inconsistencies were resolved by returning
to the source documents and assessing which record was
accurate. As some data were subject to interpretation, any
discrepancies between the two records were noted, and a
third party (JG) reviewed the data. Three investigators
(MF, VF, JG) then discussed the information. If consensus
between MF and VF could not be reached, the third party
(JG) adjudicated how the data would be recorded.
Source documents were ranked by two of the authors
(MF and VF) for confidence in confirmation of the pres-
ence and type of malignancy. These rankings were then
submitted to other members of the research team (DHS,
JG, JK, GR, MH), and a final hierarchy of the level of
confidence in the cancer diagnosis was constructed. The
hierarchy gave greater weight to objective evidence of
malignancy (pathology report) or note from the appro-
priate type of expert (e.g. oncologist, radiation oncolo-
gist, dermatologist for skin cancers, etc.). Other sources
included death certificates, admission notes, and dis-
charge summaries (Additional file 1: Table S1).
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Adjudication of malignancies
Source documents were reviewed for each malignancy; the
document with the highest hierarchical value was recorded
(see above). Malignancies were defined as “definite” if a ma-
lignancy was reported on a biopsy report or from an on-
cologist or radiation oncologist. To be considered an
incident malignancy, the date of diagnosis (month and year)
also had to be submitted, and had to have occurred after
enrollment in CORRONA. For certain malignancies, note
from an appropriate specialty was considered sufficient to
designate the case as “definite” (ex: skin cancer and derma-
tologist’s note). If the supporting documentation was a note
from another type of specialist, and the date of diagnosis
and histology were included either in the note or hand writ-
ten on adverse event form, then the diagnosis was desig-
nated “probable”. If either the histology or the date of
diagnosis were not present, then the case was designated
“possible.” In some cases, the source documents or adverse
event form noted that the case was not a malignancy. Dis-
position of reported cases is shown in Figure 1.
Statistical analysis
Outcomes for this analysis compared a gold standard
(documentation of confirmed incident malignancies) to the
CORRONA questionnaire as well as the adverse event form
report of malignancy. Positive predictive value (PPV) of
follow-up visit report and adverse event form was calcu-
lated compared to the gold standard with 95% confidence
intervals (CI).
Results
The demographics of patients in this analysis are shown
in Table 1. Of the 20,839 RA patients in the CORRONA
Registry, 401 had at least one rheumatologist-reported
malignancy during follow up, and some patients had
more than one incident malignancy reported during fol-
low up. RA patients with malignancies differed from the
subjects without malignancy: they were older (65.2 vs.
57.6 years, p< 0.0001), less likely to be female (63 vs.
73%, p <0.0001), and were more likely to be non-His-
panic White (89 vs. 84%, p = 0.0005). In addition, they
also had longer disease duration at enrollment (12.6 vs.
9.6 years, p< 0.0001) and longer duration of follow-up
within CORRONA (2.3 vs. 1.8 years, p< 0.0001). There
was no significant difference in seropositive status
between the two groups (71 vs. 68%, p = 0.31).
The various documents used to determine confidence in
the diagnosis of malignancy are shown in Table 2. Of the
461 cases, there were corroborating documents for 303
(65.7%). For cases with multiple documents, the document
with the highest validity as deemed by the authors was
used. Source documents that were able to definitely con-
firm the diagnosis were available for about half of the
reported malignancies. For 158 cases (34.3% of the reported
malignancies), there was no additional confirmation beyond
an adverse event form. Of these, 36 (22.8% without con-
firmation, 7.8% overall) were adjudicated as probable, as the
AE form submitted both a histology and an incident date.
An additional 79 (50% without confirmation, 17.1% overall)
were adjudicated as possible incident malignancy. The
remaining 43 (27.2% without confirmation, 9.3% overall)
had insufficient data on the TAE Form and they were
deemed unlikely to be an incident malignancy.
Reasons why cases were excluded (N= 57) from
categorization as incident malignancies are shown in
Figure 1. The most common reason for exclusion was
determining, usually via source documents, that there
was insufficient data to determine whether an incident
malignancy had occurred (43 cases, 75.4% of excluded,
9.3% overall). Six cases were excluded as they were
prevalent, but not incident malignancies (10.5% of
excluded, 1.3% overall). Five cases were excluded as on
corroboration, they were confirmed to not be malignan-
cies (8.8% of excluded, 1.1% overall). Lastly, 3 cases were
excluded as they were submitted twice (5.3% of
461 Physician-Reported Cases
43 cases with 
insufficient data 
to adjudicate as 
even a possible 
Malignancy
6 cases noted on 
AE form to be 
prior
to CORRONA 
enrollment
3 cases 
submitted
twice
404 Definite, Possible
or Probable Malignancies
234
Definite 69
Probable
101
Possible
5 cases 
confirmed on 
source
documents as 
Not a 
Malignancy
Figure 1 Disposition of physician reported cases*.* This
represents the results of the adjudication of the 461 reported
malignancies in 401 patients.
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excluded, 0.7% overall). All 234 definite malignancies
had corroborating data to confirm date of onset and
histology. Of the 69 probable malignancies, 36 had no
corroborating records submitted, but had an incident
date and history on the TAE form. Of the 101 possible
malignancies, 79 had no records submitted. Of the pos-
sible malignancies, 60 had a histology submitted but no
date of the malignancy. 13 had a date of the malignancy
but no histology, and 28 had both no histology and no
date.
The number and type of malignancies stratified by adju-
dicated status are found in Table 3. The most common
reported malignancies were non-melanoma skin cancers
(NMSC), 154 total cases, comprising 33.4% of all malignan-
cies. Using the gold standard of medical records review, just
under half (46.1%) of these reported NMSC could be classi-
fied as definite malignancies; adding probable cases
increased that number to 68.8%. In addition, there were 9
melanomas reported, one of which was ultimately con-
firmed not a melanoma. The second most common
reported malignancy was breast cancer (59 cases, 13% of all
reported malignancies). Five different histologies were
noted on records review (data not shown). About three-
quarters (74.6%) of reported breast cases were adjudicated
as definite or probable. Hematologic, prostate, lung, and
colon cancers all accounted for between 4.6% - and 9.1% of
the total reported malignancies. Lastly, 57 cases (11.1%)
were proven on either adverse event forms or from source
documents to actually not be an independent incident ma-
lignancy. This was most common with cancers that were
not able to be specified (71.9% of all cases deemed not an
incident malignancy). These cases were included in the
analysis as on the TAE they were confirmed as malignan-
cies by the primary site. In one case, a histology and inci-
dent date was listed but the primary organ was listed as
“unknown.” This case was deemed a definite incident
malignancy.
A comparison of the predictive value of the
CORRONA questionnaire and the adverse event form to
the gold standard of medical records review is shown in
Table 2 Hierarchy of Source Documents
Type of Document Level of Confidence* N, % Used**
Biopsy report 1 173 (57.1%)
Oncologist Note 1 58 (19.1%)
Radiation Oncologist Note 1 9 (2.3%)
Dermatologist note (skin
cancers only)
1 6 (2%)
OB-GYN Note (for OB-GYN
cancers only)
1 1 (0.3%)
Urologist Note (for GU
cancers only)
1 2 (0.7%)
Admission note 2 2 (0.7%)
Discharge summary 2 5 (1.7%)
Rheumatologist Note 2 16 (5.3%)
Other Physician Note 2 28 (9.2%)
Pharmaceutical Company
adverse event form
3 3 (1.0%)
* For Level 1, sufficient independently to confirm a diagnosis of malignancy
For level 2, if a date of diagnosis (month and year) on the adverse event form
or in the note was also provided, and a histology was submitted, defined as a
Probable malignancy. If either of that data was absent, defined as a Possible
malignancy.
For level 3, if tissue diagnosis included, defined as a Probable malignancy. If
not, defined as a Possible malignancy.
** For cases with multiple source documents, only the document with the
highest hierarchical value was used. 303 cases had submitted documents
(Total N).
Table 1 Patient Demographics
Total CORRONA
Population
Total CORRONA Patients Without
Malignancy
Total CORRONA Patients With
Malignancies
P-
Values
(N = 20,839) (N= 20,438) (N = 401)**
Age (Mean, SD) 57.7 (13.6) 57.6 (13.9) 65.2 (11.0) <.0001
Female Gender (N, %) 15,135 (72.8%) 14,883 (73.0%) 252 (62.8%) <.0001
Race/Ethnicity (N, %)
White 17,292 (84.0%) 16,940 (84.0%) 352 (88.7%) 0.0005
Hispanic 1,291 (6.3%) 1,275 (6.3%) 16 (4.0%)
Black 1,248 (6.1%) 1,238 (6.1%) 10 (2.5%)
Asian 344 (1.7%) 340 (1.7%) 4 (1.0%)
Other 418 (2.0%) 403 (2.0%) 15 (3.8%)
Seropositivity (N, %) 7,400 (67.7%) 7,224 (67.6%) 176 (70.7%) 0.31
RA Disease Duration at Enrollment in CORRONA
(mean years, SD)
9.56 (9.8) 9.49 (9.8) 12.56 (11.3) <.0001
Years of Follow-up After CORRONA Enrollment
Until Report of Cancer* (mean, SD)
1.76 (1.6) 1.75 (1.8) 2.26 (1.7) <.0001
* follow-up time censored at the time of the first report of an incident malignancy.
** 44 patients had multiple malignancies reported, for a total of 461 reported malignancies.
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Table 4. Using only definite and probable cases, the
questionnaire had a positive predictive value (PPV) of
0.66 (95% CI 0.61 – 0.70). If possible cases were added,
this increased to 0.86 (95% CI 0.83 – 0.89). If informa-
tion from the TAE form was also used, the PPV was 0.68
(95% CI 0.63 – 0.72) for definite and probable cases. If
possible cases were included, the PPV increased to 0.89
(95% CI 0.85 – 0.91).
Discussion
Accurate classification of incident malignancies is essential
for pharmacoepidemiologic studies, as well as to compare
rates between different cohort studies and assess the rela-
tionship between disease characteristics and treatments
with the development of cancer. Patient self-report may be
an imperfect method for ascertaining incident malignan-
cies, as the difference between a benign mass and true
Table 3 Reported Incident Malignancy Types by Adjudication
Organ or
Type of
Malignancy
Physician
Form
Records Review –
Definite*
Records Review –
Probable**
Records Review –
Possible***
Records Review – Not Malignancy
or Not An
Incident Malignancy****
(Total: 461) (Total: 234) (Total: 69) (Total: 101) (Total: 57)
Skin – NMSC1 154 71 (46.1%) 35 (22.7%) 42 (27.3%) 6 (3.9%)
Skin –
Melanoma
9 5 (55.6%) 1 (11.1%) 2 (22.2%) 1 (11.1%)
Skin – Other2 5 4 (80%) 1 (20%) 0 0
Breast 59 41 (69.5%) 3 (5.1%) 13 (22.0%) 2 (3.4%)
Hematologic4 42 32 (76.2%) 7 (16.7%) 3 (7.1%) 0
Other3 49 1 (2.0%) 0 7 (14.3%) 41 (83.7%)
Prostate 38 21 (55.3%) 4 (10.5%) 11 (29%) 2 (5.3%)
Lung 25 11 (44.0%) 2 (8%) 9 (36%) 3 (12%)
Colon5 21 13 (61.9%) 5 (23.8%) 3 (14.3%) 0
Thyroid 9 3 (33.3%) 5 (55.5%) 1 (11.1%) 0
Bladder 12 6 (50%) 2 (16.7%) 3 (25%) 1 (8.3%)
Head and
Neck6
7 4 (57.1%) 2 (28.6%) 1 (14.3%) 0
Uterine 5 3 (60%) 0 1 (20%) 1 (20%)
Upper GI7 4 4 (100%) 0 0 0
Renal 4 2 (50%) 1 (25%) 1 (25%) 0
Cervical 3 1 (33.3%) 0 2 (66.7%) 0
Ovarian 3 2 (66.7%) 0 1 (33.3%) 0
Pancreatic 2 2 (100%) 0 0 0
Bile duct 1 1 (100%) 0 0 0
Parotid Gland 2 1 (50%) 0 1 (50%) 0
Brain 2 1 (50%) 1 (50%) 0 0
Hepatic 2 2 (100%) 0 0 0
Peritoneum 1 1 (100%) 0 0 0
Gallbladder 1 1 (100%) 0 0 0
Angiosarcoma 1 1 (100%) 0 0 0
1) Includes 47 squamous cell, 91 basal cell, and 16 unspecified.
2) Includes vulvar, anal, perianal, intergluteal skin cancers.
3) Includes all malignancies with unspecified primary organ.
4) Includes 36 lymphomas, 1 Myeloma, 3 Leukemia, 2 Myelodysplasia.
5) Includes Rectal, anal, bowel, small intestine, appendix.
6) Includes Larynx, tongue, vocal cord, nasopharyngeal.
7) Includes esophageal and gastric.
* Definite malignancy defined as date of diagnosis and histology confirmed on records from an oncologist, biopsy, radiation oncologist, or appropriate specialist
for specific cancers.
** Probable malignancy defined as date of diagnosis and histology confirmed from records other than oncologist, biopsy, radiation oncologist, or appropriate
specialist.
*** Possible malignancy defined as submission of records confirming either date of
diagnosis or histology but not both.
**** Not Malignancy or Not An Incident Malignancy defined as records confirming pathology were benign or date of diagnosis prior to enrollment in CORRONA
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neoplasm is not always clearly communicated or under-
stood. Even physician report may be unreliable, as the treat-
ing rheumatologist may not have the primary information
about an incident malignancy. Administrative databases
based on claims data are also not ideal, as the methodology
used to define malignancy can cause the positive predictive
value to vary widely [21,22]. We attempted to validate phys-
ician report of incident malignancy based on physician
questionnaires and adverse event forms using a gold stand-
ard of pertinent medical records review in a large cohort of
patients with RA. We were able to confirm approximately
two-thirds of reported incident malignancies. We found
that having a positive report of incident malignancy on the
adverse event forms increased the PPV only slightly com-
pared to questionnaires alone. However, the PPV of the
physician report alone may not be sufficiently high enough
to be relied on for epidemiologic purposes. Hence, use of
non-validated reports of incident malignancy might over-
estimate the true incidence in patients with RA and might
bias the results of pharmacoepidemiologic studies assessing
causal associations with specific treatments.
Our second notable finding was the exclusion of 14
malignancies (3.0%) because they were either duplicate
entries, established cancers that were not incident, or
proven by corroborating documents to not be malignant.
An additional 43 cases (9.3%) had insufficient data and
could not even be deemed possible malignancies. Clearly
some of those are incident cases, although it is not clear
how many. In addition, 101 cases (21.9%) could at best
be classified as possible incident malignancies (either
histology report or date of diagnosis missing). The ac-
curacy of classifying cancer in a study assessing the risk
of different treatments is important. If the possible ma-
lignancies are dismissed as non-cancers, it might artifi-
cially create a sense of decreased risk for a given
medication, when at least some of those cases are likely
to be true malignancies. Alternatively, including all pos-
sible malignancies might change the perception of the
risk/benefit ratio and prevent patients or physicians from
choosing a medication that could have benefit. The first
approach would provide greater specificity; however, this
is at the sacrifice of sensitivity. Assessing both rates
would provide a range within which the true value most
likely exists, but also illustrates the degree of uncertainty
generated by physician report and even follow-up ad-
verse event forms.
Our third significant finding was that despite follow-
up with the primary treating rheumatologist, almost a
third of the time, we could not obtain source documents
to corroborate the malignancy. In some cases, this may
be due to lack of diligence by the site. However, in most
cases, this was because records truly could not be
obtained. As a result, since 2008 the registry now
requests source documents at the time the cancer is ini-
tially reported, to avoid requesting records of events
from multiple years earlier. This proactive approach has
improved the proportion of cases with source
documents.
The methodology defines the classification of the malig-
nancies, as it does depend on appropriate documentation
submitted from the patient’s rheumatologist. The use of ap-
propriate specialists for specific malignancies, such as a
dermatologist for a skin cancer or a urologist for a geni-
tourinary cancer, was deemed appropriate as for those ma-
lignancies where that specialist will treat the patient
directly, as opposed to having an oncologist manage treat-
ment. All ‘possible’ malignancies were classified as such be-
cause of some inadequacy of the requisite data to have
confidence that it was truly an incident case.
The type of dataset itself also can impact the rate of
malignancy found in a given population. The intensity of
evaluation is much higher in a clinical trial, and virtually
all cases of malignancy during the follow-up period
would be expected to be reported. However, Phase II
and III randomized controlled trials only follow patients
with a single intervention for a finite period, and thus
cannot offer the kind of data that can be possible in a
long-term disease registry. It is possible that the intensity
of surveillance itself can impact clinical care and out-
come (Hawthorne effect), but it is still unclear if it will
affect the overall incidence of a specific comorbidity
such as malignancy in patients with RA.
The strengths of this analysis include the use of a very
large dataset which includes information gathered from
both providers and patients in the context of an established
infrastructure which permitted the identification and fol-
low-up of all reported cases. This allowed us to procure
source documents in most cases. In addition, we used a
standardized record review process with multiple adjudica-
tors. All of these steps increased the validity of the results.
This study did have certain weaknesses as well. Al-
though standard questions on the development of new
malignancies were included in both the physician and
patient questionnaires at each visit, it is still possible that
some malignancies were not reported. As previously
noted, the absence of a national cancer registry in the
US makes independent assessment of new malignancies
extremely difficult if not impossible. As such, we cannot
Table 4 Predictive Values versus Gold Standard of
Records Review
PPV Physician
Questionnaire (95% CI)
PPV Adverse Event
Form (95% CI)
0.66 0.68
Definite/Probable (0.61–0.70) (0.63–0.72)
0.86 0.89
Definite/Probable/
Possible
(0.83–0.89) (0.85–0.91)
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calculate a negative predictive value of the default evalu-
ation of “no malignancy.” Individual state cancer regis-
tries are available, are sponsored by both the NCI and
the CDC, and their reliability continues to improve,
though they are not reflective of nationwide rates, as the
SEER data is. However, identification of individual
patients requires the use of personal health information
(PHI), and the CORRONA consent does not permit the
use of PHI to cross-link with other registries. In
addition, despite repeated attempts to obtain source
documents, in many cases none were available. This led
to the classification of many malignancies as “possible,”
even while reported independently on the primary ques-
tionnaire from either the patient or treating physician.
Certainly many of these cases likely were true malignan-
cies. We believe that this problem is likely to be endemic
to all observational registry studies in the absence of a
national cancer registry. The response rate for pertinent
records did improve when cases were reported to COR-
RONA more recently. However, there was no significant
difference in rate of excluded cases (either not an inci-
dent malignancy or confirmed to be not a malignancy)
from earlier versus more recent cases. A cancer registry
where all malignancies are reported and validated, as is
frequently done outside the United States, is superior to
our methodology. However, information from within the
United States is still of great value, as drug utilization
patterns in the US are quite different from European
registries where penetration of biologic agents is signifi-
cantly greater than in Europe[23,24]. We therefore be-
lieve that it is critical to appropriately analyze data on
major comorbidites from a US source.
Conclusions
In conclusion, our process of confirming malignancies
started with the identification of possible cases reported
at the time of a routine clinic visit. It was further refined
through subsequent hierarchical steps which included a
targeted adverse event form and subsequent review and
ranking of available source documents by a team of phy-
sicians. As a result of these rigorous adjudication steps,
we found that routine reports of malignancy by patients
and physicians were not always accurate. The implica-
tions of over and underreporting in large disease registry
may be epidemiologically significant. We believe that it
would be ideal if uniform standards for reporting of
these events could be adopted in observational disease
registries where cancer registries are not available.
Additional file
Additional file 1: Table S1. Rank of Source Documents.
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